Total trials
625
Active
154
Phase 3
31
Total enrollment
249,331
Pipeline matrix
Showing 40 of 42 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 2 | |
| Caffeine | — | — | — | — | — | 1 | |
| Daratumumab SC in combination with Lenalidomide | — | — | — | — | — | 1 | |
| Lenalidomide PO | — | — | — | — | — | 1 | |
| Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression | — | — | — | — | — | 1 | |
| Clomiphene Citrate | — | — | — | — | — | 1 | |
| Apixaban 5 MG | — | — | — | — | — | 1 | |
| Cryotherapy + Tirbanibulin | — | — | — | — | — | 1 | |
| N-Acetylcysteine (NAC) Treatment | — | — | — | — | — | 1 | |
| Prednisolone 10mg | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 2 | |
| Teclistamab | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Intramuscular Islet Autograft | — | — | — | — | — | 1 | |
| Vismodegib | — | — | — | — | — | 1 | |
| TRIXEO AEROSPHERE | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 1 | |
| Benralizumab 30 MG/ML [Fasenra] | — | — | — | — | — | 1 | |
| rapamycin | — | — | — | — | — | 1 | |
| Rapamycin dosage | — | — | — | — | — | 1 | |
| DRF | — | — | — | — | — | 1 | |
| EXL01 | — | — | — | — | — | 1 | |
| intraportal islet autotransplantation | — | — | — | — | — | 1 | |
| fluoroethyl-L tyrosine | — | — | — | — | — | 1 | |
| Surgery with Neoadjuvant stereotactic body radiation therapy | — | — | — | — | — | 1 | |
| CAR-T cell therapy | — | — | — | — | — | 1 | |
| Packed Red Blood Cells | — | — | — | — | — | 1 | |
| blood sample | — | — | — | — | — | 2 | |
| blood test | — | — | — | — | — | 2 | |
| Venous sample | — | — | — | — | — | 1 | |
| ofatumumab | — | — | — | — | — | 1 | |
| Systemic treatment | — | — | — | — | — | 1 | |
| Biological sample | — | — | — | — | — | 1 | |
| Biobanking with genetic analysis | — | — | — | — | — | 1 | |
| Large and early multigene sequencing | — | — | — | — | — | 1 | |
| Biological biomarkers | — | — | — | — | — | 1 | |
| DNA banking | — | — | — | — | — | 1 | |
| Biologic treatments available in CRSwNP | — | — | — | — | — | 1 | |
| Diagnosis of SPAD using immunization with PPV23 | — | — | — | — | — | 1 |
2 more active programs hidden
Next readouts
- 2026-04
- 2026-04
- 2026-05-09
- 2026-06
- 2026-07
- 2026-08
- 2026-09
- 2026-10
- 2026-10-07
- 2027-02
Top conditions
- Obesity14
- Sars-CoV214
- Critical Illness11
- Stroke10
- Parkinson Disease9
- Multiple Sclerosis9
- Systemic Sclerosis9
- Inflammatory Bowel Diseases8
Frequently asked questions about University Hospital, Lille
- How many clinical trials does University Hospital, Lille have on ClinicalTrials.gov?
- University Hospital, Lille is listed as the lead sponsor on 625 clinical trials in ClinicalTrials.gov, 154 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Lille's trials are in Phase 3?
- 31 of University Hospital, Lille's trials are in Phase 3, spread across 42 active drug programs.
- What therapeutic areas does University Hospital, Lille focus on?
- University Hospital, Lille's most-studied conditions on ClinicalTrials.gov are Obesity, Sars-CoV2, Critical Illness, Stroke, Parkinson Disease.
- When are University Hospital, Lille's next clinical trial readouts?
- University Hospital, Lille has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma”, expected around 2026-04.